Navigation Links
Grifols Establishes Expert Advisory Council in Transfusion Medicine

BARCELONA, Spain, March 7, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it has established an Expert Advisory Council in Transfusion Medicine drawing on the expertise of internationally renowned physicians and researchers from across the globe.  The role of the Expert Advisory Council is to provide insight, advice and guidance to Grifols' own transfusion medicine research and development activities.


"Bringing together these leaders in transfusion medicine underscores our longstanding commitment to being a world leader in blood diagnostics and transfusion medicine," said Eva Bastida, Ph.D, Scientific Director of Grifols. "Working with this team of experts will bring new perspectives to shape our strategic goals and plans," continued Dr. Bastida.  Grifols Diagnostics is focused on the development of cutting-edge technologies for use in clinical laboratories and blood banks.

"It is an honor to serve with my transfusion medicine colleagues on the Grifols Expert Advisory Council," said Mr. John Moulds, MT (ASCP) director of Scientific Support Services at LifeShare Blood Centers, Shreveport, Louisiana who serves as the Council Chair.  "Working with such a highly esteemed group of thought leaders will no doubt bear fruit that will help shape future directions in transfusion medicine," stated Mr. Moulds.  

Grifols has a seventy-year history of advancing blood diagnostics and transfusion medicine remains a core part of its business today.  With input from the Expert Advisory Council Grifols will continue to advance its mission of improving hemovigilance, transfusion safety, and the quality of life for people who receive blood transfusions.  The broad geographic diversity of Advisory Council members is expected to stimulate creative new approaches to current transfusion medicine challenges.  

Grifols portfolio of products and services cover every link of the transfusion chain: blood bags and donation kits, blood component separators, autoanalyzers and reagents for pre-transfusion analytical tests (blood typing and donor-recipient compatibility studies) and blood bank management software, among others.

Members of the Advisory CouncilThe Advisory Council is chaired by Mr. John Moulds, MT (ASCP) director of Scientific Support Services at LifeShare Blood Centers,  Shreveport, Louisiana, USA, and its membership consists of nine globally respected experts from different countries.  Members of the Grifols Advisory Council on Transfusion Medicine include:Dr. Jill R. Storry, Ph.D.Docent / Assoc. ProfessorKIT / Clinical Immunology and Transfusion Medicine Labmedicin Skane University and Regional Laboratories Lund - SWEDENProf. Dr. Lilian Castilho, PhDCoordinator, Blood Center of CampinasCEP Campinas SP  - BRAZILDr. Miquel Lozano, MD, PhDChief of the Hemotherapy Section of the Department of Hemotherapy and Hemostasis, Hospital Clinic of Barcelona, Barcelona, Spain.Dr. Arthur Bracey, MDMedical Director, Transfusion ServicesSt. Luke's Episcopal HospitalHouston, TX - USProf. W. John Judd, FIBMS, MIBiolPresident and CEOImmunohematology Consulting, LLCSupply, NC - USDr. Mark Yazer, MD FRCPCAssociate Professor of Pathology, University of PittsburghMedical Director, RBC Serology Reference Laboratory, Centralized Transfusion Service, The Institute for Transfusion MedicinePittsburgh, PA US Dr. Yoshihiko Tani, MD, PhDJapanese Red Cross Osaka Blood Center - JAPANProf. Neil AventHead of School School of Biomedical and Biological SciencesUniversity of Plymouth, Plymouth, UKDr. Jacques  Chiaroni Directeur de l'Etablissement Francais du Sang Alpes-MediterraneeMarseille, FRANCEAbout GrifolsGrifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 Grifols has been listed on the Spanish Continuous Market, and has been included in the Ibex-35 since 2008.  Grifols focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies.  In recent years Grifols has made significant investments in the area of transfusion medicine to advance its mission of improving hemovigilance, transfusion safety, and the quality of life for people who receive blood transfusions.  For more information visit


SOURCE Grifols
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
4. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
5. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
6. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
7. Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US
8. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Pharmaxis Establishes Named Patient Program for Bronchitol
11. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical ... for cardiovascular conditions via the inhalation route, today announced ... Australia . InCarda is planning to undertake ... in the first half of 2016. The ... in Adelaide and Melbourne.  In ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Trustify is proud to announce the success of the seventh ... organization dedicated to ending domestic violence. , Trustify and Becky’s Fund have joined forces ... of domestic violence. Trustify is also proud to announce the launch of the company’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, ... Tennessee to receive Gigabit Internet through a partnership this year with Aeneas Internet ... Henderson is an attractive destination for entrepreneurs who want to build a business. ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and ... believe that with innovative technologies and under the right circumstances, these practices can ... benefit of a dual-approach to his or her therapeutic sessions, as well as ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
Breaking Medicine News(10 mins):